BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04493853 (Capivasertib in Hormone-Sensitive Prostate Cancer): BVCT ex-ante prediction vs. reported outcome

On 19 Aug 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 26 Nov 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially TBD.

Clinical Trial

NCTID
NCT04493853
Acronym
CAPItello-281
Drug Name
Capivasertib
Drug MoA
pan-ATK small molecule inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Hormone-Sensitive Prostate Cancer
Human Patients
1012
Sponsor
AstraZeneca
Phase
Phase 3

Prediction of , index 1761

Prospective Prediction
Prediction Index
1761
Prediction Date
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in OS)
Technical Prediction
SUCCESS (statistically significant additive clinical benefit in rPFS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
99 days in advance
Readout Data Interpretation
capivasertib + SoC achieved superior rPFS compared with SoC alone; OS data not mature
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially TBD
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.
Phase
Phase 3
Status
Active not recruiting
Enrollment
1012
Lead sponsor
AstraZeneca
Conditions
Hormone-Sensitive Prostate Cancer
Interventions
DRUG: Capivasertib; OTHER: Placebo; DRUG: Abiraterone Acetate
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2020-07-13
Primary completion
2024-10-07
Completion
2027-03-31
Results first posted
2026-09-10
Primary outcomes
  • Radiographic Progression-free Survival (rPFS) (Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized)

NCT04493853 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials